版權(quán)說明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
ARTIFICIALSKINMaierdanjiangWufuer買爾旦江吾甫爾DepartmentofPlasticandReconstructiveSurgery,InstituteofHuman-EnvironmentInterfaceBiology,CollegeofMedicine,SeoulNat’lUniversity,Seoul,RepublicofKoreaBiomedicalResearchInstitute,SeoulNat’lUniv.Hospital,Seoul,RepublicofKoreaARTIFICIALSKINMaierdanjiangW1Apligraf?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSA,Organogenesis,Inc.Epidermal/DermalreplacementKeratinocytes
fromhumanneonatalforeskintissueBovinecollagenIgelwithallogeneicNOFDA1998,approvedforuseinthetreatmentofdiabeticfootulcersandvenouslegulcers.37'incubator,viablefor2-3daysdifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReference10days1.Preparewound2.Applyapligraf3.DresswoundWounddressingwithtwodifferentcelltypes,3timesfasterhealingindifficultwounds/Mostexpensive,shortshelf-life$1,100./42cm2abilaminarstructureformedbytype
Ibovinecollagengelpopulatedbyliveneonatal
fibroblastscoatedwithalayerofepithelialcellsWilkinsLM,WatsonSR,ProskySJ,etal.Developmentofabilayeredlivingskinconstructforclinicalapplications.BiotechnolBioeng.1994;43747-756.2.ParenteauNL,NolteCM,BilboP,etal.Epidermisgeneratedinvitro:practicalconsiderationsandapplications.JCellBiochem.1991;45:245-251Apligraf?CountryObjectiveEpid2OrCel?CountryObjectiveEpidermisDermis/Matrix
STG?FDA&IndicationstoragUSA,ForticellBioscienceInc.,NYEpidermal/dermalreplacementkeratinocytesderivedfromneonatalforeskin,Bovinecollagenspongewithallogeneicfibroblastsandkeratinocytes）no2001,FDAapprove,partial-thicknesswounds37'incubatordifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReference37'incubator1.Preparewound2.Applyorcel3.Dresswoundwhereitprovidesafavourablematrixforhostcellmigration.expensive$1,200/44cm2OrCel?
isabilayerdressingresemblingnormalskinandwasdevelopedasatissue-engineeredbiologicaldressing./orcel-technology/OrCel?CountryObjectiveEpidermi3Integra?CountryObjectiveEpidermisDermis/Matrix
SG?FDA&IndicationstoragUSA,IntegraLifeSciencesCorp.,NJ,Dermalreplacementsilicone/Syntheticpolysiloxanepolymer/thatactsskinepidermis.Itprotectsthewoundfrominfectionandcontrolsbothheatandmoistureloss.Thedermallayerismadeofa3Dporousmatrixofcross-linkedcollagen(purecollagenfromcows)andglycosaminoglycan.(glycosaminoglycanmadefromsharkcartilage).yesFDAIn1996,treatmentoflifethreateningburinjuriesand2014thereconstructionofscarcontractures.EachsheetofIntegratemplateisstoredin
phosphatebufferwithinafoilpouch.Eachsterilefoilpouchispackagedinasealedouterchevron-style
pouch.
flatat2°–30°C.Protectfromfreezing.differentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceNO1.Day21+:SiliconeRemoval2.Day21+:epidermalautograftHasthesomeoftheadvantagesofanautograftwithoutadonorsite.Oncethesiliconesheetbeginstoseparatewithvascularizationofthecollagenmatrix,itisremovedandengineeredtissueplacedoverthisbed
orSTSGusedIntheabsenceoflivingcells,itisverydifficulttoseehowonecouldcreateapermanentartificialdermalbarrier.
isabi-layered
extracellularmatrixoffibersofcross-linkedbovinecollagenandchondroitin-6-sulfate(acomponentof
cartilage)withsiliconebacking.Onceanorganizedregenerationofdermaltissueisformed(neodermis),thedisposablesiliconesheetisremovedandanultrathinautograftisplacedovertheneodermis.1.-
I.V.Yannas;"Designofanarti?cialskinII:Controlofchemicalcomposition."Integra?CountryObjectiveEpider4Dermagraft?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSA,OrganogenesisInc.,MADermalreplacementNOlivingallogeneicfibroblastsonapolyglactinmesh.YESFDA-approvedfordiabeticulcers,treatdeeperwounds.
Inabox/pouch.Preservedat-70°Cwith6-monthshelf-lifedifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceno1.Preparewound2.Apply3.Dresswound.Thepolyglactinmeshisbiodegradableandisreabsorbedafter
3to4weeks.includealackofhostimmuneresponse,easeof
applicationandresistancetotearingAsDermagrafthasnoepidermalcomponent,clinicianshaveuseditwithasubsequentapplicationofasplitthicknessskingraft.2*3CM,$1500perapplicationThefibroblastscomefromneonatalforeskinandremainviableafterimplantation,continuingtosecretematrixproteinsandgrowthfactors./home/Dermagraft?CountryObjectiveEp5Epicel?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSA,GenzymeCorporation,CambridgeMA,EpidermalcoverCulturedsubstitute:autologouskeratinocyteswithmurinefibroblastsN0NOsuperficialwounds.
37'incubatordifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceTheproductismadefromabiopsyofthepatient’sownskin,whichissubsequentlyculturedforthreeweeks.Epicel?consistsofsheetsofautologouskeratinocytesattachedtoapetrolatumgauzesupport,whichisremovedapproximately1weekaftergraftingTheabilitytoexpandepidermalcellsinvitroandproduceautologousculturedepitheliumwasanimportantbreakthroughinburntherapyincludecostanddelayofapplicationduetothethree-weekgraftcultivation.Ithasnodermalcomponentandisaccordinglysuitedformoresuperficialwounds.
Thepatient’sownskincellsare
grownorculturedfromapostage‐stampsizedsampleofthepatient’sownhealthyskin.Theskincells
aregrownonalayerofirradiatedmousecells,makingEpicel?axenotransplantationproduct.Epicel?CountryObjectiveEpiderm6TransCyte?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSADermalreplacementOuterepidermalanalogisathinnonporoussiliconemesh-likematerialwithbarrierfunctionsInnerdermalanalogislayeredwithhumanfibroblastproductsmainlycollagentype1,fibronectinandGlycosaminoglycanYESItistypicallyusedtotreatseconddegreeburnfrozendifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceHumanFibroblastDerivedTemporarySkinSubstituteTemporarywoundcoveringforsurgicallyexcisedfullthicknessandpartialthicknessburns.Thiscryopreservedmatrixcontainshighlevelsofproteinsandgrowthfactorswithnoviablecells.NeedtostorefrozentilluseRelativelyexpensiverequirementofmultipleapplications
HumanFibroblastDerivedTemporarySkinSubstitute
Temporarywoundcoveringforsurgicallyexcisedfullthicknessandpartialthicknessburns.
anoutersiliconelayer(withnopores)TransCyte?CountryObjectiveEpid7Alloderm?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSA,LifeCellCorporation,Bridgewater,NJDermalreplacementNONon-livingdermalreplacementcomposedofhumancadavericskininwhichtheepidermishasbeenremovedbysaltprocessing.
yesbothacuteandchronicwounds.freeze-drieddifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceNO1.Preparewound2.Apply3.Dresswound.ofAllodermincludealongshelflifebecauseitisfreezedried,
immediateavailabilityandminimalriskforhostimmunologicresponse.ofthisproductincludetheriskofdiseasetransmission.
Thereisnoepidermalcomponentso
clinicianscommonlyusetheproductwithasplit-thicknessskingraft.AlloDermsupportstissueregenerationbyallowingrapidrevascularization,whitecellmigrationandcellpopulation-ultimatelybeingtransformedintohosttissueforastrong,naturalrepair./alloderm.aspxAlloderm?CountryObjectiveEpide8Oasis?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSA,
CookBiotech,Inc.DermalreplacementNOintactmatrixnaturallyderivedfromporcinesmallintestinalsubmucosa(SIS),YESpartial-andfull-thicknesswounds,pressureulcers,venousulcers,chronicvascularulcers,Roomtemperatureandon-the-shelfstorage/Long2-yearshelflifedifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferencePrepareApplyAnchorRehydrate5.Dress6.Cover7.Reassess8.Reapplyevery7daysReapplyOASIS?WoundMatrixevery7daysorasneeded,Ifagelformsonthewoundsurface,donotattempttoforciblyremove.Gentlyrinsethewoundsurface,leavingtheextracellularmatrix(ECM)gelintact.Long2-yearshelflife
Minimallyprocessedandsterilizedusingaproprietarymethodthatallowslong-termstorageofthestructurewithoutcompromisingitsabilitytosupportthebody’sowntissuerepairmechanisms2/application-wound-matrixOasis?CountryObjectiveEpidermi9Matriderm?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragGermany,MedSkinSolutionsDr.SuwelackAG,BillerbeckDermalreplacementNOmatrixcontainingI,II,andV-typecollagenextractedfrombovineligamentanddermis,andalpha-elastinhydrolysates.IYESacuteburnwoundsandscarreconstructionprocedures.RoomtemperaturedifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceItcanbeappliedconcurrentlywiththesplit-thicknessskingraftItcanbeappliedconcurrentlywiththesplit-thicknessskingraftappliedtogetherwithasplitskingraf,,secondarysurgeryisnotrequiredThematrixservesasasupportstructurefortheingrowthofcellsandvessels.
Matriderm?CountryObjectiveEpid10Biobrane?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSADermalreplacementOuterepidermalanalog—ultrathinsiliconefilm;innerdermalanalog—3DnylonfilamentwithtypeIcollagenpeptidesYESThetreatmentisspecifictononinfectedpartial-thicknessburnwoundsanddonorsitewounds,RTdifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceBiobraneisappliedandheldinplacewithspecialglue.Biobranewilltakebetween10-14days.BiobranehasbeenshowntoreducethepainanddiscomfortfeltwhentheskinisscaledTemporarywounddressingthatisremovedwhenwoundishealedorwhenautograftskinisavailableBiobrane?wasfirstintroducedforthetreatmentofburnwoundsanddonorsitesin197911.SmithDJ.UseofBiobraneinwoundmanagement.JBCRMay/June1995:16(3)Supplement;317-320.Biobrane?CountryObjectiveEpide11Theraskin?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSAEpidermal/dermalreplacementhumanskinallograft,composedoflivingcells,keratinocyteshumanskinallograft,fibroblastsandafullydevelopedextracellularmatrix(ECM)initsepidermisanddermislayers.NOnon-healingchronicwoundTheraSkiniscryopreserved(-70oC)differentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceLandsman,A.(2010).Aretrospectiveclinicalstudyofconsecutivepatientstoexaminetheeffectiveness1.Preparewound2.Apply3.Dresswound.Providesabroadspectrumofthemajorgrowthfactorsforwoundhealingabiologicallyactive,cryopreservedhumanskinallograftwithbothepidermisanddermislayers.Itscellularandextracellularcompositionprovidesasupplyofgrowthfactors,cytokinesandcollagentopromotewoundhealing./upload/docs/Healthcare%20Services/Wound-Healing/retrospective-study2.pdfTheraskin?CountryObjectiveEpid12Epicel?
(GenzymeTissueRepair).Epicelisaculturedautograftcomposedoflivingkeratinocytes.Theproductismadefromabiopsyofthepatient’sownskin,whichissubsequentlyculturedforthreeweeks.
Ithasnodermalcomponentandisaccordinglysuitedformoresuperficialwounds.
Inadditiontoservingasapermanentskinreplacement.Itcanalsocoveralargewoundarea.
Disadvantagesincludecostanddelayofapplicationduetothethree-weekgraftcultivation.Epicel?
(GenzymeTissueRepair1314Alloderm?
(LifeCell)Allodermisanacellular,Non-livingdermalreplacementcomposedofhumancadavericskininwhichtheepidermishasbeenremovedbysaltprocessing.
Theproductisfreeze-driedandhasbeenusedinbothacuteandchronicwounds.Thereisnoepidermalcomponentso
clinicianscommonlyusetheproductwithasplit-thicknessskingraft.AdvantagesofAllodermincludealongshelflifebecauseitisfreezedried,
immediateavailabilityandminimalriskforhostimmunologicresponse.Disadvantagesofthisproductincludetheriskofdiseasetransmission.
14Alloderm?
(LifeCell)Alloder15Matriderm?IsanacelulardermalsubstuitutesisastructurallyintactmatrixofbovineI,II,andV-typecollagenwithelastin.Itisutilisedfordermalregeneration.Itsindicationsarefullthicknessordeepdermalburnwoundsandchronicwounds.Thematrixservesasasupportstructurefortheingrowthofcellsandvessels.
Itselastincomponentimprovesthestabilityandelasticityoftheregeneratingtissue.(SkinandHealthCareAG,Billerbeck,Germany)15Matriderm?IsanacelularderARTIFICIALSKINMaierdanjiangWufuer買爾旦江吾甫爾DepartmentofPlasticandReconstructiveSurgery,InstituteofHuman-EnvironmentInterfaceBiology,CollegeofMedicine,SeoulNat’lUniversity,Seoul,RepublicofKoreaBiomedicalResearchInstitute,SeoulNat’lUniv.Hospital,Seoul,RepublicofKoreaARTIFICIALSKINMaierdanjiangW16Apligraf?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSA,Organogenesis,Inc.Epidermal/DermalreplacementKeratinocytes
fromhumanneonatalforeskintissueBovinecollagenIgelwithallogeneicNOFDA1998,approvedforuseinthetreatmentofdiabeticfootulcersandvenouslegulcers.37'incubator,viablefor2-3daysdifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReference10days1.Preparewound2.Applyapligraf3.DresswoundWounddressingwithtwodifferentcelltypes,3timesfasterhealingindifficultwounds/Mostexpensive,shortshelf-life$1,100./42cm2abilaminarstructureformedbytype
Ibovinecollagengelpopulatedbyliveneonatal
fibroblastscoatedwithalayerofepithelialcellsWilkinsLM,WatsonSR,ProskySJ,etal.Developmentofabilayeredlivingskinconstructforclinicalapplications.BiotechnolBioeng.1994;43747-756.2.ParenteauNL,NolteCM,BilboP,etal.Epidermisgeneratedinvitro:practicalconsiderationsandapplications.JCellBiochem.1991;45:245-251Apligraf?CountryObjectiveEpid17OrCel?CountryObjectiveEpidermisDermis/Matrix
STG?FDA&IndicationstoragUSA,ForticellBioscienceInc.,NYEpidermal/dermalreplacementkeratinocytesderivedfromneonatalforeskin,Bovinecollagenspongewithallogeneicfibroblastsandkeratinocytes）no2001,FDAapprove,partial-thicknesswounds37'incubatordifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReference37'incubator1.Preparewound2.Applyorcel3.Dresswoundwhereitprovidesafavourablematrixforhostcellmigration.expensive$1,200/44cm2OrCel?
isabilayerdressingresemblingnormalskinandwasdevelopedasatissue-engineeredbiologicaldressing./orcel-technology/OrCel?CountryObjectiveEpidermi18Integra?CountryObjectiveEpidermisDermis/Matrix
SG?FDA&IndicationstoragUSA,IntegraLifeSciencesCorp.,NJ,Dermalreplacementsilicone/Syntheticpolysiloxanepolymer/thatactsskinepidermis.Itprotectsthewoundfrominfectionandcontrolsbothheatandmoistureloss.Thedermallayerismadeofa3Dporousmatrixofcross-linkedcollagen(purecollagenfromcows)andglycosaminoglycan.(glycosaminoglycanmadefromsharkcartilage).yesFDAIn1996,treatmentoflifethreateningburinjuriesand2014thereconstructionofscarcontractures.EachsheetofIntegratemplateisstoredin
phosphatebufferwithinafoilpouch.Eachsterilefoilpouchispackagedinasealedouterchevron-style
pouch.
flatat2°–30°C.Protectfromfreezing.differentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceNO1.Day21+:SiliconeRemoval2.Day21+:epidermalautograftHasthesomeoftheadvantagesofanautograftwithoutadonorsite.Oncethesiliconesheetbeginstoseparatewithvascularizationofthecollagenmatrix,itisremovedandengineeredtissueplacedoverthisbed
orSTSGusedIntheabsenceoflivingcells,itisverydifficulttoseehowonecouldcreateapermanentartificialdermalbarrier.
isabi-layered
extracellularmatrixoffibersofcross-linkedbovinecollagenandchondroitin-6-sulfate(acomponentof
cartilage)withsiliconebacking.Onceanorganizedregenerationofdermaltissueisformed(neodermis),thedisposablesiliconesheetisremovedandanultrathinautograftisplacedovertheneodermis.1.-
I.V.Yannas;"Designofanarti?cialskinII:Controlofchemicalcomposition."Integra?CountryObjectiveEpider19Dermagraft?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSA,OrganogenesisInc.,MADermalreplacementNOlivingallogeneicfibroblastsonapolyglactinmesh.YESFDA-approvedfordiabeticulcers,treatdeeperwounds.
Inabox/pouch.Preservedat-70°Cwith6-monthshelf-lifedifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceno1.Preparewound2.Apply3.Dresswound.Thepolyglactinmeshisbiodegradableandisreabsorbedafter
3to4weeks.includealackofhostimmuneresponse,easeof
applicationandresistancetotearingAsDermagrafthasnoepidermalcomponent,clinicianshaveuseditwithasubsequentapplicationofasplitthicknessskingraft.2*3CM,$1500perapplicationThefibroblastscomefromneonatalforeskinandremainviableafterimplantation,continuingtosecretematrixproteinsandgrowthfactors./home/Dermagraft?CountryObjectiveEp20Epicel?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSA,GenzymeCorporation,CambridgeMA,EpidermalcoverCulturedsubstitute:autologouskeratinocyteswithmurinefibroblastsN0NOsuperficialwounds.
37'incubatordifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceTheproductismadefromabiopsyofthepatient’sownskin,whichissubsequentlyculturedforthreeweeks.Epicel?consistsofsheetsofautologouskeratinocytesattachedtoapetrolatumgauzesupport,whichisremovedapproximately1weekaftergraftingTheabilitytoexpandepidermalcellsinvitroandproduceautologousculturedepitheliumwasanimportantbreakthroughinburntherapyincludecostanddelayofapplicationduetothethree-weekgraftcultivation.Ithasnodermalcomponentandisaccordinglysuitedformoresuperficialwounds.
Thepatient’sownskincellsare
grownorculturedfromapostage‐stampsizedsampleofthepatient’sownhealthyskin.Theskincells
aregrownonalayerofirradiatedmousecells,makingEpicel?axenotransplantationproduct.Epicel?CountryObjectiveEpiderm21TransCyte?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSADermalreplacementOuterepidermalanalogisathinnonporoussiliconemesh-likematerialwithbarrierfunctionsInnerdermalanalogislayeredwithhumanfibroblastproductsmainlycollagentype1,fibronectinandGlycosaminoglycanYESItistypicallyusedtotreatseconddegreeburnfrozendifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceHumanFibroblastDerivedTemporarySkinSubstituteTemporarywoundcoveringforsurgicallyexcisedfullthicknessandpartialthicknessburns.Thiscryopreservedmatrixcontainshighlevelsofproteinsandgrowthfactorswithnoviablecells.NeedtostorefrozentilluseRelativelyexpensiverequirementofmultipleapplications
HumanFibroblastDerivedTemporarySkinSubstitute
Temporarywoundcoveringforsurgicallyexcisedfullthicknessandpartialthicknessburns.
anoutersiliconelayer(withnopores)TransCyte?CountryObjectiveEpid22Alloderm?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSA,LifeCellCorporation,Bridgewater,NJDermalreplacementNONon-livingdermalreplacementcomposedofhumancadavericskininwhichtheepidermishasbeenremovedbysaltprocessing.
yesbothacuteandchronicwounds.freeze-drieddifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceNO1.Preparewound2.Apply3.Dresswound.ofAllodermincludealongshelflifebecauseitisfreezedried,
immediateavailabilityandminimalriskforhostimmunologicresponse.ofthisproductincludetheriskofdiseasetransmission.
Thereisnoepidermalcomponentso
clinicianscommonlyusetheproductwithasplit-thicknessskingraft.AlloDermsupportstissueregenerationbyallowingrapidrevascularization,whitecellmigrationandcellpopulation-ultimatelybeingtransformedintohosttissueforastrong,naturalrepair./alloderm.aspxAlloderm?CountryObjectiveEpide23Oasis?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSA,
CookBiotech,Inc.DermalreplacementNOintactmatrixnaturallyderivedfromporcinesmallintestinalsubmucosa(SIS),YESpartial-andfull-thicknesswounds,pressureulcers,venousulcers,chronicvascularulcers,Roomtemperatureandon-the-shelfstorage/Long2-yearshelflifedifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferencePrepareApplyAnchorRehydrate5.Dress6.Cover7.Reassess8.Reapplyevery7daysReapplyOASIS?WoundMatrixevery7daysorasneeded,Ifagelformsonthewoundsurface,donotattempttoforciblyremove.Gentlyrinsethewoundsurface,leavingtheextracellularmatrix(ECM)gelintact.Long2-yearshelflife
Minimallyprocessedandsterilizedusingaproprietarymethodthatallowslong-termstorageofthestructurewithoutcompromisingitsabilitytosupportthebody’sowntissuerepairmechanisms2/application-wound-matrixOasis?CountryObjectiveEpidermi24Matriderm?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragGermany,MedSkinSolutionsDr.SuwelackAG,BillerbeckDermalreplacementNOmatrixcontainingI,II,andV-typecollagenextractedfrombovineligamentanddermis,andalpha-elastinhydrolysates.IYESacuteburnwoundsandscarreconstructionprocedures.RoomtemperaturedifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceItcanbeappliedconcurrentlywiththesplit-thicknessskingraftItcanbeappliedconcurrentlywiththesplit-thicknessskingraftappliedtogetherwithasplitskingraf,,secondarysurgeryisnotrequiredThematrixservesasasupportstructurefortheingrowthofcellsandvessels.
Matriderm?CountryObjectiveEpid25Biobrane?CountryObjectiveEpidermisDermis/Matrix
graft?FDA&IndicationstoragUSADermalreplacementOuterepidermalanalog—ultrathinsiliconefilm;innerdermalanalog—3DnylonfilamentwithtypeIcollagenpeptidesYESThetreatmentisspecifictononinfectedpartial-thicknessburnwoundsanddonorsitewounds,RTdifferentiationApplicationAdvantagesDisadvantagesPriceMoreinfoReferenceBiobraneisappliedandheldinplacewithspecialglue.Biobranewilltakebetween10-14days.BiobranehasbeenshowntoreducethepainanddiscomfortfeltwhentheskinisscaledTemporarywounddressingthatisremovedwhenwoundishealedorwhenautograftskinisavailableBiobrane?wasfirstintroducedforthetreatmentofburnwoundsanddonorsitesin197911.SmithDJ.UseofBiobraneinwoundmanagement.JBCRMay/June1995:16(3)Supplement;317-320.Biobrane?
溫馨提示
- 1. 本站所有資源如無特殊說明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽，若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間，僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請與我們聯(lián)系，我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 一年級下冊語文教學(xué)反思
- 產(chǎn)品加工買賣合同范本
- 雙方合同范本寫
- 《常見的酸和堿》經(jīng)典教學(xué)反思
- 廠房外墻噴漆合同范例
- 變更代理合同范本
- 入股合同范本合伙協(xié)議模板
- 債務(wù)廠房抵押合同范本
- 公司委托物業(yè)合同范本
- 印刷包裝簽單合同范例
- 2024-貸款受托支付合同模板
- 柴油發(fā)電機(jī)基礎(chǔ)知識教案
- 2024年蘇州衛(wèi)生職業(yè)技術(shù)學(xué)院單招職業(yè)適應(yīng)性測試題庫及答案解析
- 十萬個(gè)為什么測試題及答案四年級
- 攝影基礎(chǔ)基本知識講座
- JTG 5110-2023 公路養(yǎng)護(hù)技術(shù)標(biāo)準(zhǔn)
- 2022年蘇州工業(yè)職業(yè)技術(shù)學(xué)院單招數(shù)學(xué)模擬試題(附答案解析)
- 2024年證券投資基金基礎(chǔ)知識真題答案及解析
- 泰州職業(yè)技術(shù)學(xué)院單招《英語》考試參考題庫（含答案）
- 《食品衛(wèi)生與安全》課程標(biāo)準(zhǔn)
- 第7課《誰是最可愛的人》公開課一等獎(jiǎng)創(chuàng)新教學(xué)設(shè)計(jì)-2
評論
0/150
提交評論